4.6 Article

Perioperative Hemostatic Management of Patients Treated with Vitamin K Antagonists

期刊

ANESTHESIOLOGY
卷 109, 期 5, 页码 918-926

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/ALN.0b013e3181895bd8

关键词

-

资金

  1. Novo Nordisk, Princeton, New Jersey
  2. CSL Behring, King of Prussia, Pennsylvania,
  3. Octapharma, Centreville, Virginia

向作者/读者索取更多资源

Clinicians, including anesthesiologists, surgeons, and intensivists, are frequently called on to correct coagulopathy in patients receiving oral anticoagulation therapy. Before elective surgery, anticoagulation reversal may be undertaken over several days by discontinuing warfarin or vitamin K treatment, but rapid correction is required in an emergency. European and American guidelines recommend prothrombin complex concentrates (PCCs) for anticoagulation reversal in patients with life-threatening bleeding and an increased international normalized ratio. Compared with human fresh frozen plasma, PCCs provide quicker correction of the international normalized ratio and improved bleeding control. Although there are historic concerns regarding potential infectious and thrombotic risks with PCCs, current PCC formulations are much improved. Recombinant activated factor VII is a potential alternative to PCCs, but preclinical comparisons suggest that PCCs are more effective in correcting coagulopathy. Although many patients who require rapid reversal of warfarin are currently treated with fresh frozen plasma, PCCs should he considered as an alternative therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据